CANTANHEDE, Portugal, Dec. 22, 2025 /PRNewswire/ -- Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selection of its lead clinical candidate, ZE00-0388, a highly selective inhibitor of...
Hence then, the article about mondego bio announces selection of a ptpn2 inhibitor clinical candidate and targets first in human trials in h1 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026 )
Also on site :
- 'The chances of you living 50 years are very small': Theoretical physicist explains why humanity likely won't survive to see all the forces unified
- Ohio man's detour for tomatoes yields $3 million lottery win
- The Strokes End Coachella Performance With Video Montage Condemning U.S. and Israeli Bombings in Iran and Gaza